31 research outputs found
PCN12 COST EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) IN POLAND
Get PDF
PCN21 BUDGET IMPACT ANALYSIS OF NON – SMALL CELL LUNG CARCINOMA (NSCLC) TREATMENT WITH ERLOTINIB IN POLISH SETTING
No full textPUK8 CMA OF MYCOPHENOLAN MOFETIL (MMF; CELLCEPT) OR TACROLIMUS (TAC; PROGRAF) IN KIDNEYTRANSPLANT IMMUNOSUPPRESSIVE THERAPY SCHEMES FROM PUBLIC PAYER'S PERSPECTIVE IN POLAND
No full textPCN12 COST EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) IN POLAND
No full textPCN77 COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA
No full textPUK5 COSTS AND COST-EFFECTIVENESS OF EPOETIN IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY DURING THE PREDIALYSIS PERIOD IN POLAND
No full textPCN4 BUDGET IMPACT ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING
No full textDirect Costs of Treatment of Skin Drug Reactions Induced by Antibiotics in Perspective of Public Payer and Service Provider
No full text
